Meeting Banner
Abstract #0951

Validation of contralateral parenchymal enhancement on DCE-MRI as a biomarker of survival in patients with ER-positive/HER2-negative breast cancer

Bas H.M. van der Velden1, Elizabeth J. Sutton2, Luca A. Carbonaro2,3, Ruud M. Pijnappel4, Elizabeth A. Morris2, and Kenneth G.A. Gilhuijs1

1Image Sciences Institute, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 3Unità di Radiologia, IRCCS Policlinico San Donato, Milan, Italy, 4Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands

This study was performed to validate whether MR contrast-enhancement in stromal tissue of the disease-free breast is related to the survival of patients with cancer in the other breast. A recent study in 398 patients with estrogen-receptor positive and human-epidermal-growth-factor-2 negative invasive breast cancer showed that more pronounced contralateral parenchymal enhancement (CPE) was associated with improved patient survival. In this study, we extracted CPE to re-test the finding in a comparable patient population from an independent cancer center. In 287 patients, CPE reproduces as a biomarker for long-term survival. This reproducible imaging finding has potential towards the personalization of care.

This abstract and the presentation materials are available to members only; a login is required.

Join Here